ENANTA PHARMACEUTICALS, INC Amortization of Debt Issuance Costs
ENANTA PHARMACEUTICALS, INC (ENTA) reported Amortization of Debt Issuance Costs of $4.80 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC amortization of debt issuance costs for the quarter ending 2026-06-30 was $0.00.
- ENANTA PHARMACEUTICALS, INC amortization of debt issuance costs for the quarter ending 2026-03-31 was $0.00.
- ENANTA PHARMACEUTICALS, INC amortization of debt issuance costs for the quarter ending 2025-12-31 was $4.80M.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $4.80M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $4.80M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $4.80M 10-Q · filed 2026-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |